Rosuvastatin Calcium

Rosuvastatin Calcium Chinese Synonyms (3R,5S,6E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonamido)-5-pyrimidinyl]-3,5-dihydroxy-6-heptenoic acid calcium salt; Superstatin Calcium; Rosuvastatin Calcium; Rosuvastatin Calcium; (3R,5S,6E)-7-[4-(4-Fluorophenyl); Rosuvastatin Calcium (Superstatin Calcium); Rosuvastatin Calcium Reference Standard; Rosuvastatin; Rosuvastatin Calcium English Name Rosuvastatin Calcium English Synonyms 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)-; (3R,5S,6E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl])-3,5-dihydroxyhept-6-enoic acid hemicalcium salt; Rosuvastatin Calcium (W.S); ZD4522 Calcium; ROSUVASTATIN CALCIUM (ROSUVASTATIN HEMICALCIUM); Rosuvastadine; Rosuvastatin Calcium (3R,5S,6E)-7-[4-(4-fluorophenyl)-6-(1-Methylethyl)-2-[N-Methyl(n-Methylsulfonyl)aMino]-5-pyriMidinyl]-3,5-dihydroxy-6-Heptenoic calcium; Rosuvastatin Calcium CAS Number 147098-20-2 Molecular Formula C22H30CaFN3O6S Molecular Weight 523.63 EINECS Number 627-028-1 Related Categories Pharmaceuticals & Bio-Chemicals; Active Pharmaceutical Ingredients; Rosuvastatin Calcium; Signal Transduction Pathway Kinase Inhibitors; Cardiovascular and Cerebrovascular Research APIs; Pharmaceutical Intermediates; Endocrinology and Hormones; Intermediates; API; Impurity Reference Standards; Small Molecule Inhibitors; Inhibitors; Small Molecule Inhibitors, Natural Products; Pharmaceutical Raw Materials; Pharmaceutical APIs; Reference Standards; Medical Raw Materials; Cardiovascular and Cerebrovascular; Chemical Products - Organic Chemicals; Medical Raw Materials; Drug Impurities and Intermediates; Impurity Reference Standards; Raw Materials; Pharmaceutical, Pesticide, and Dye Intermediates; Traditional Chinese Medicine Reference Standards; Organic Chemical Raw Materials; Chemical Intermediates; Daily Chemicals; Chemical Reagents; Industrialization; Active Pharmaceutical Ingredients; Statins’ Anti-Lipidemia Agents; Intermediates & Fine Chemicals; Pharmaceuticals; Rosuvastatin; HMG-COA reductase, Hypolipidemic drugs; rosuvastatin calcium R; API; Aromatics; Chiral Reagents; Sulfur & Selenium Compounds; DERMATOP Mol File 147098-20-2.mol Structural Formula Rosuvastatin Calcium Properties Melting Point 122°C Specific Rotation D24 +14.8° (c=1.012 in 50% methanol) Storage Conditions 2-8°C Solubility DMSO: 25 mg/mL (49.94 mM; requires sonication) H2O: 1 mg/mL (2.00 mM; requires sonication) Form Powder Color White to beige Optical Activity [α]/D +12 to +18°, c=1 in methanol:water (1:1) Maximum Wavelength (λmax) 243 nm (Phosphate buffer sol.) (lit.) Merck 14,8270 InChI Key JSVIQRTVYKCCOM-LMRKSJJTNA-N SMILES C(/C1=C(N=C(N(C)S(=O)(=O)C)N=C1C1C=CC(F)=CC=1)C(C)C)=C\[C@@H](O)C[C@@H](O)CC(=O)O.[Ca]|&1:24,27,r| CAS Database 147098-20-2 (CAS DataBase Reference) Rosuvastatin Calcium Uses and Synthesis Methods Anti-hyperlipidemia Drug Rosuvastatin Calcium is an anti-hyperlipidemia drug, belonging to the HMG-CoA reductase inhibitors, developed by AstraZeneca in the UK. It is suitable for treating various lipid abnormalities, including hypercholesterolemia, mixed dyslipidemia, and isolated hypertriglyceridemia. Rosuvastatin Calcium is currently the most potent lipid-lowering drug on the market with the most comprehensive lipid-regulating effects. It has better efficacy in lowering LDL cholesterol and increasing HDL cholesterol compared to atorvastatin, which is widely recognized as the most effective drug. It also offers better tolerability, fewer side effects, and unique pharmacokinetic characteristics, with a half-life of about 20 hours, requiring only once-daily administration. Pharmacological Effects Rosuvastatin is a selective HMG-CoA reductase inhibitor. HMG-CoA reductase is the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of cholesterol. The primary site of action of Rosuvastatin is the liver, the target organ for cholesterol reduction. Rosuvastatin increases the number of hepatic LDL cell surface receptors, promotes LDL uptake and catabolism, and inhibits hepatic synthesis of VLDL, thereby reducing the total number of VLDL and LDL particles. For patients with homozygous and heterozygous familial hypercholesterolemia, non-familial hypercholesterolemia, and mixed dyslipidemia, Rosuvastatin can reduce total cholesterol, LDL-C, ApoB, and non-HDL-C levels. Rosuvastatin also lowers TG and increases HDL-C levels. For patients with isolated hypertriglyceridemia, Rosuvastatin can reduce total cholesterol, LDL-C, VLDL-C, ApoB, non-HDL-C, and TG levels, and increase HDL-C levels. Preclinical data based on general safety pharmacology, repeated dose toxicity, potential genotoxicity, and carcinogenicity studies did not reveal any specific toxicity to humans. In pre- and postnatal studies in rats, Rosuvastatin showed reproductive toxicity, reducing litter size, weight, and survival rate. These reproductive toxicities were observed when maternal systemic exposure was several times higher than the therapeutic exposure level at toxic doses. The above information was compiled by Jinwei of ChemicalBook. Pharmacokinetics This product is extensively taken up by the liver after oral administration, with a distribution volume of about 134 L. The peak plasma concentration is reached in 3–5 hours. The absolute bioavailability is 20%. Plasma protein binding (mainly albumin) is about 90%. Approximately 90% of the dose of Rosuvastatin is excreted unchanged in feces (including absorbed and unabsorbed active substance), with the remainder excreted through urine. About 5% is excreted unchanged in urine. The plasma elimination half-life is about 19 hours. The elimination half-life does not increase with dose. The geometric mean plasma clearance is about 50 L/h (coefficient of variation 21.7%). Like other HMG-CoA reductase inhibitors, hepatic uptake of Rosuvastatin involves the membrane transporter OATP-C. This transporter is important for the hepatic clearance of Rosuvastatin. Drug Interactions 1. Cyclosporine: When co-administered with cyclosporine, the AUC of Rosuvastatin is on average 7 times higher than that observed in healthy volunteers (compared to the same dose of this product alone). Co-administration does not affect the plasma concentration of cyclosporine. 2. Vitamin K Antagonists: Like other HMG-CoA reductase inhibitors, initiating or increasing the dose of this product in patients taking vitamin K antagonists (e.g., warfarin) may lead to an increase in INR (International Normalized Ratio). Discontinuing or reducing the dose of this product may lead to a decrease in INR. In such cases, appropriate monitoring of INR is required. 3. Gemfibrozil, Fenofibrate, Other Fibrates, and Lipid-Lowering Doses (≥1 g/day) of Niacin: Co-administration with HMG-CoA reductase inhibitors increases the risk of myopathy, which may be due to the fact that these drugs alone can cause myopathy. 4. Antacids: Concurrent administration of this product and an antacid suspension containing aluminum and magnesium hydroxide reduces the plasma concentration of Rosuvastatin by about 50%. This effect is reduced if the antacid is administered 2 hours after taking this product. The clinical significance of this drug interaction has not been studied. 5. Erythromycin: Co-administration of this product with erythromycin results in a 20% decrease in AUC (0–t) and a 30% decrease in Cmax of Rosuvastatin. This interaction may be due to increased gastrointestinal motility caused by erythromycin. 6. Oral Contraceptives/Hormone Replacement Therapy (HRT): Concurrent use of this product and oral contraceptives increases the AUC of ethinyl estradiol and norgestrel by 26% and 34%, respectively. These increases in plasma concentrations should be considered when selecting the dose of oral contraceptives. There are no pharmacokinetic data for subjects using this product concurrently with HRT, so a similar interaction cannot be ruled out. However, in clinical trials, this combination was widely used and well tolerated by patients.